We retrospectively studied 108 marrow harvests from 105 pediatric sibling donors. The median age of donors was 8 years (range: 1-15) and the median body weight was 27 kg (range: 10-100). The volumes of aspirated marrow were 5.0-23.8 mL/kg donor body weight, and harvested bone marrow volume exceeded 15 mL/kg in 42% of the donors. A total of 100 autologous blood donations were performed, and eight donors had red cells salvaged from their harvests reinfused. The median Hb levels before and after harvests were 12.3 g/dL (range: 10.0-14.7) and 11.0 g/dL (range: 8.9-13.8), respectively. None of the donors received allogeneic blood transfusions or hematopoietic growth factors such as EPO and G-CSF before or after collection. Transplanted dose was 1.4-10.8 × 10 8 cells/kg recipient body weight without differences due to donor age. Higher concentrations of nucleated and CD34 + cells were obtained from younger donors. All donors tolerated the procedures well, with no serious complications. Thus, children may safely donate marrow for allogeneic transplantation, and the yields of nucleated cells for engraftment are substantial.
INTRODUCTION
Hematopoietic SCT has become a standard treatment for many diseases, and children often serve as donors for their siblings. Although the use of peripheral blood and umbilical cord blood has increased, the primary source of stem cells is the BM for pediatric patients. 1 Pediatric donors must be evaluated to ensure that the harvested cells will be sufficient for transplantation into the recipients and that the donation process is safe, especially with respect to the risk of allogeneic blood transfusions after BM harvest. To avoid the allogeneic blood transfusions that most young children and infant donors require, 2,3 some groups administer recombinant human EPO. 4 Other groups recommend using G-CSF-primed BM to get a higher BM cell yield, which is expected to lead to more rapid engraftment. 5, 6 Our trial demonstrated the feasibility of bone marrow harvesting from pediatric donors without allotransfusion or mobilizing factors, perhaps making them the best control group for evaluating subsequent effects in healthy donors. The purpose of this article is to describe in detail all facets of marrow harvesting that relate to engraftment and all events and complications that have occurred in pediatric BM donors.
MATERIALS AND METHODS

Study design
Between 1982 and 2011, Tokai University Hospital conducted 151 harvesting procedures from 142 pediatric donors who under 16 years. Out of these 151 harvesting procedures, we excluded 43, and data before 1992 were missing in 84 (missing data: harvested volume, 6; total number of nucleated cells at harvest, 2; transfusion history, 5; allotransfusion volume, 2; autotransfusion volume, 10; preharvest Hb level, 10; postharvest Hb level, 27; number of aspirations, 22), and none of the pediatric donors had any severe adverse events. We retrospectively studied the laboratory data and BM reports available for 108 marrow harvests (72%) from 105 pediatric sibling donors (74%). Three donors had donated twice because of primary graft failure or leukemia relapse. The Tokai University Hospital Institutional Review Board approved the collection and reporting of donor and recipient data from medical records.
BM donor procedure for marrow collection
Written informed consent was obtained from each donor and/or their parents or legal guardians. The BM donation procedure consisted of the following steps:
1. A medical evaluation including blood tests, urinalysis, chest X-ray, electrocardiogram and pulmonary function test, if possible, was done to ensure the health of the potential donor. 2. If the volume of harvested marrow was to be more than 10 ml/kg of donor weight, 8-10 ml of blood per kilogram was collected twice, at most, from the donor 2-5 weeks before the harvest. During the preparation of autologous blood collection, anticoagulant in the bag was reduced according to the expected harvest blood volume, and the original needle from the blood collection bag was replaced with a thinner needle, set by using a blood bag thermosealer under sterile conditions. Topical lidocaine tape was applied to the skin above the median cubital vein or the cephalic vein, at least 1 h before venipuncture. Under supervision of the parents, the lidocaine tape was removed, and the skin was sterilized using alcohol as well as povidone iodine, followed by venipuncture. Following venipuncture, the blood collection bag was placed on the platform scale and was shaken diligently to mix the blood and anticoagulant. An oral iron supplement was administered after each autologous blood collection until BM harvest. 3. Most donors entered the hospital one day before harvesting, and were subjected to physical and laboratory examinations. 4. Marrow collection was performed from the posterior iliac crests under general anesthesia. Autologous blood transfusion was given during the collection. Red cells were salvaged in a semiautomated closed system and were reinfused eight times into seven donors. These donors were donor-recipient pairs who were ABO incompatible. Samples were obtained for cell count, colony assays, bacteriologic cultures, and, since 2000, CD34 + cell quantification (in 26 donors) by flow cytometry analysis using a stem cell enumeration kit system from Becton Dickinson (San Jose, CA, USA). 5. Prophylactic antibiotics were administered postoperatively, and a blood test was conducted to check for anemia and infection the day after the harvest. 6. Most donors were discharged 2 days after the harvest and scheduled for follow-up evaluation 2-4 weeks after the harvest.
We compared the concentration of nucleated marrow cells harvested from the pediatric donors with 100 other donors aged 16-54 years who were treated at the Tokai University Hospital. We also compared the absolute CD34 + cell count in the marrow harvests from 26 pediatric donors with 34 donors aged 16-54 years.
Patients
One hundred and four patients received allogeneic BMT from 95 HLAidentical and 10 HLA-mismatched siblings. A second transplantation was completed on three patients, and a different sibling was used once for the second procedure.
Statistical analysis
Statistical analysis was performed with Prism version 5.0 (GraphPad Software, San Diego, CA, USA). Comparative analysis was done with the Pearson correlation coefficient, and the Kruskal-Wallis test yielded a P-value where a statistical difference was detected at a significance level of 0.05.
RESULTS
Donor characteristics
A total of 108 procedures with preparations from 105 donors were performed on 104 recipients. Table 1 shows donor and recipient characteristics.
Characteristics of the marrow harvests and engraftment Table 2 Autologous blood transfusion A total of 100 autologous blood transfusions were performed with 98 donors, and 20% of the youngest group of donors participated in two autologous blood donations (Table 3) . A larger volume of blood by per kilogram of donor weight was more likely to be collected from younger donors. The staff and family, usually the mother, supported or comforted the donor throughout blood donation. No severe complications related to autologous blood collection were observed. None of the donors received allogeneic blood transfusions and EPO. A Hb level below 10.0 g/dL was observed in only six (5.6%) donors after harvest; nevertheless, these donors still received autologous blood transfusions. Four of these donors were unable to tolerate oral iron supplementation after blood collection, and five donors were classified in the lower D/R weight ratio group (0.32-0.83).
Before 1996, reinfusion of salvaged red cells had been performed in eight donor-recipient pairs who displayed major ABO incompatibility. In three of the donors, we had difficulty completing autologous blood collection (Cases 2, 4 and 5 in Table 4 ), and we attempted to salvage red cell reinfusion. Five donors received both salvaged red cell reinfusion and an autologous blood transfusion to avoid progression of anemia, because their harvest volume was large (Cases 1, 3, 6, 7 and 8 in Table 4 ). As we were able to collect autologous blood after 1997, we did not perform red blood cell reinfusion. Complications related to BM harvest and hospital stay Donors were hospitalized for 3-9 days (median: 4). Postoperative fever greater than 38.0°C was observed in two donors, and preoperative fever caused by pharyngitis was seen in two donors. All of these episodes resolved without complications. Asthmatic bronchitis developed after general anesthesia in one donor who was treated with steroids and discharged after 4 days of hospitalization. Most patients complained of pain following the aspiration procedure, although the pain was described as mild, and did not require analgesics, whereas five donors received oral analgesic agents and one received intravenous pentazocine. All donors tolerated the procedures well, and no serious side effects occurred. All bacteriologic cultures of harvested BM were negative. In total, 71 patients survived for 2-30 years after BMT, and 19 of the 34 patients who eventually died, survived for at least 1 year after BMT. Therefore, we were able to confirm that there were no serious complications for 90 donors, for at least 1 year after BM harvest from their family members. 9 found that cellularity of pediatric BM, including healthy donors, was highest in patients younger than 2 years (approximately 80%), declined to approximately 60% by the age of 5 years, and then remained relatively constant in patients aged 5-18 years. One separate study showed that the marrow aspirated from donors less than 2 years of age contained a relatively large number of nucleated cells per volume of collected marrow, 3 and another reported that increasing donor age appeared to be associated with reduction in the number of nucleated cells, 2 an observation similar to our finding. Our study found that a sufficient numbers of nucleated cells were obtained in each age group of donors, and the differences between them were insignificant. Moreover, we were able to show that a sufficient infused cell dose could be safely obtained from the lower D/R weight ratio group of donors (Figures 1a-c) . Although younger donors were more likely to donate smaller volumes per kilogram of recipient weight, their harvested cells contained a higher concentration of nucleated cells (Figure 2a) . We also showed that younger donors yielded higher concentrations of CD34 + cells (Figure 2b ). Age-related changes in human hematopoietic stem/ progenitor cells have been reported, 10 as has the lack of an association in adults between age and any progenitor cell subtype in BM. 11 However, the effect of aging on human hematopoietic stem cells in BM has not been sufficiently analyzed in children. Set analysis of our data confirmed that younger pediatric BM donors provided a larger number of nucleated cells and CD34 + cells for their body weight and small build was not a barrier to the collection of either BM cells or allogeneic peripheral blood stem cells from normal pediatric donors. 12 Some groups recommend using G-CSF-primed BM to get a higher BM cell dose, expecting to minimize BM collection volume from donors and enhance the speed of engraftment in patients. 5, 6 Although G-CSF administration before marrow or peripheral blood stem cell collection appears to be safe and effective, G-CSF causes temporary discomfort in younger donors, 13 and long-term effects following G-CSF treatment are unknown because of the limited number of donors who have been followed up.
DISCUSSION
14 Pediatric donors are more likely than adults to receive allogeneic blood transfusion. Walraven et al. 8 reported that in 65% of 109 donations, the harvest volumes exceeded 15 mL/kg, and more than half required allogeneic blood transfusion. The risk of needing an allotransfusion after BM harvest was associated with a donor age of less than 4 years and a BM harvest volume of greater than 20 mL/kg body weight in a prospective study of the European Group for Blood and Marrow Transplantation Pediatric Disease Working Party, where 84 of the 313 BM donors required allotransfusion. 7 Sanders et al. 3 reported that 22 of 23 marrow donors under the age of 2 years required allogeneic blood. Although serious complications of allotransfusion among pediatric donor are rare, unexpected events, including acute or delayed immunologic reactions, viral hepatitis and retrovirus transmission, occur. Therefore, allotransfusion in pediatric donors should be avoided when possible. Preoperative autologous donation (PAD) programs have been instituted widely to reduce the risks of allotransfusions, 15 but there have been few reports of its use in 17 Masuda et al. 18 reported that postoperative recovery of Hb with a concurrent increase in reticulocytes was significantly better in a PAD group of patients with a cardiac anomaly than in a control group treated with homologous blood. In our study, we successfully collected autologous blood in 100 procedures on 98 donors aged 1-15 years (weight: 10.0-100.0 kg) without any severe complications, such as infection, thrombosis or embolism. We established a standard to maintain Hb levels above 10.0 g/dL after harvesting. However, as a European group had previously demonstrated that the risk of an allotransfusion was associated with a BM harvest volume of>20 mL/kg donor weight, we found it necessary to reset the standard for autologous blood donation.
For children, reinfusion of autologous red blood cells from the collected BM may be especially useful. Kletzel et al. 19 evaluated the use of a semiautomated processing technique to salvage red blood cells from 13 pediatric BM donors to minimize the risk of severe anemia following BM harvest and ABO incompatibility in the recipient. The authors concluded that the procedure was safe and it reduced the risk of anemia in pediatric donors following BM harvest. Our study examined reinfusion of salvaged red cells into eight donors, five of whom also received an autotransfusion. Although there was little difference in the eight donors with respect to Hb levels before harvest and after donation, red blood cell reinfusion was not absolutely necessary in all cases.
Martinez et al. 4 showed that 11 low-weight (less than 30 kg) pediatric BM donors who were administered recombinant human EPO for 3 weeks avoided transfusion and displayed no side effects from the treatment. However, little information is available regarding the long-term effects of using recombinant human EPO in healthy pediatric donors as in the case of G-CSF.
Generally, BMT with a pediatric marrow donor is considered an acceptable procedure. In a survey of marrow transplant physicians in pediatrics, only seven of 56 physicians would wait until the donor is older than 6 months of age, and only six of 52 responders would limit collections to 25% or less of the donor's blood volume, whereas 24 placed the limit at more than 50%. 20 The committee of Hematopoietic Stem Cell Transplantation of the Japanese Pediatric Hematology and Oncology Society recommends against harvesting marrow from donors less than 1 year old. It might be technically difficult to harvest BM from infant donors lacking bone maturation. 21 The committee also recommends that the standard volume of aspirated marrow should be 10-15 mL/kg recipient body weight and that the volume of autologous blood donation should be calculated by the following expression: (estimated volume of harvested marrow in milliliters) minus (10 mL/kg times the donor's weight in kilograms). In a single procedure, we typically collect autologous blood in the range of 8-10 mL/kg donor weight. We limit the number of procedures to two and the maximum donation to 400 mL from a single donation.
In conclusion, younger pediatric BM donors provided a larger number of nucleated cells and CD34 + cells for their body weight, and sufficient infused cell dose was obtained in the lower D/R weight ratio group. In our study, successful autologous blood donation could be performed in most pediatric donors, ages >1 year (weight: >10 kg), which could diminish the risk of allotransfusion. Moreover, the use of autologous blood donation and hematopoietic growth factors should be discussed carefully. As pediatric transplant physicians, we need to create general recommendations for donor eligibility and standard harvesting procedures, including the number of donations per donor, the maximum volume per donation, the use of autologous blood donation and mobilizing agents.
